Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging therapies and the addition of new indications will drive the market to treat ST-elevation myocardial infarction (STEMI) to increase nearly 30% by 2015. New therapies include the Medicines Company's cangrelor and bivalirudin, which have already launched as anticoagulants under the brand names Angiomax, Angiox, and Hirulog.

The new Pharmacor report entitled ST-Elevation Myocardial Infarction finds that bivalirudin and cangrelor will increase sales by $180 million in the STEMI market by 2015. The report also finds that the practice of percutaneous coronary intervention (PCI) will continue to grow in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, thereby fueling the current debate among physicians whether it is best to administer bare metal or drug-eluting stents to treat the disease.

"Percutaneous coronary intervention is now considered to be the gold standard reperfusion treatment for STEMI," said Jeremy Goldman, analyst at Decision Resources, Inc. "As a result, the number of PCIs being performed continues to increase, and an infrastructure is developing that enables more PCIs to be undertaken. Also, owing to an effort to reduce restenosis -- the narrowing of a coronary artery after angioplasty or stenting -- we estimate that the use of drug-eluting stents in the United States has tripled since 2003."

About Percutaneous Coronary Intervention

Percutaneous Coronary Intervention refers to the placement in a patient of an angioplasty guide wire, balloon, or other device such as a stent into a coronary artery for the purpose of mechanical coronary revascularization.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Contact:   Elizabeth Marshall   Decision Resources, Inc.   +1-781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Millions of Europeans Affected Each Year by Peripheral Vascular Disease

View Now